Format

Send to

Choose Destination
Cytotherapy. 2018 Nov;20(11):1381-1400. doi: 10.1016/j.jcyt.2018.09.001. Epub 2018 Oct 10.

Proceedings of the signature series symposium "cellular therapies for orthopaedics and musculoskeletal disease proven and unproven therapies-promise, facts and fantasy," international society for cellular therapies, montreal, canada, may 2, 2018.

Author information

1
Department of Orthopedic Surgery and Biomedical Engineering Cleveland Clinic, Cleveland, Ohio, USA; Instituto Universitario del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
2
Laboratory of Cellular Therapy, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena and Reggio Emilia, Modena, Italy.
3
MTF Biologics, Edison, New Jersey, USA.
4
Adult Reconstruction-Adolescent and Young Adult Hip Service, Washington University in St. Louis, School of Medicine, St. Louis, Missouri, USA.
5
Orthopaedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York, USA.
6
Department of Orthopaedic Surgery, UTHealth Medical School, Houston, Texas, USA; Steadman Philippon Research Institute, Vail, Colorado, USA.
7
INSERM, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Nantes University School of Dental Medicine, ONIRIS, Nantes, France; CHU Nantes, PHU4 OTONN, Nantes, France.
8
Advanced Regenerative Manufacturing Institute, Manchester, New Hampshire, USA, and Standards Coordinating Body, Gaithersburg, Maryland, USA.
9
Orthopaedic Research Center and Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, USA.
10
Vetbiobank, Marcy l'Etoile, France.
11
Skeletal Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA.
12
Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, New York, USA.
13
Stem Cell Allogeneic Transplant Section, National Institutes of Health, Bethesda, Maryland, USA.
14
Regenerative Medicine Institute, National University of Ireland, Galway, Ireland.
15
Steadman Philippon Research Institute, Vail, Colorado, USA; Greyledge Technologies, LLC, Vail, Colorado, USA.
16
Department of Orthopaedic Surgery, Stanford University, Stanford, California, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
17
University of Vermont College of Medicine, Burlington, Vermont, USA.
18
Department of Biomedicine, University Hospital of Basel, University of Basel, Basel, Switzerland.
19
Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Hôpital Lapeyronie, Montpellier, France.
20
Department of Orthopedic Surgery and Biomedical Engineering Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: muschlg@ccf.org.

Abstract

The Signature Series Symposium "Cellular Therapies for Orthopaedics and Musculoskeletal Disease Proven and Unproven Therapies-Promise, Facts and Fantasy" was held as a pre-meeting of the 26th International Society for Cellular Therapy (ISCT) annual congress in Montreal, Canada, May 2, 2018. This was the first ISCT program that was entirely dedicated to the advancement of cell-based therapies for musculoskeletal diseases. Cellular therapies in musculoskeletal medicine are a source of great promise and opportunity. They are also the source of public controversy, confusion and misinformation. Patients, clinicians, scientists, industry and government share a commitment to clear communication and responsible development of the field. Therefore, this symposium convened thought leaders from around the world in a forum designed to catalyze communication and collaboration to bring the greatest possible innovation and value to patients with musculoskeletal conditions.

PMID:
30316562
DOI:
10.1016/j.jcyt.2018.09.001

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center